Vivo Bio Tech profit and loss

Latest FY25
Revenue
₹46.7cr+4.0% on FY24
EBITDA
₹20.8cr−1.4% on FY24
Net profit
₹7.6cr+200.2% on FY24
EPS
₹4.95+192.9% on FY24
₹ crore except per share
Tap a line for its trendFY25Mar 2025FY24Mar 2024
46.744.9
4.80.0
51.544.9
Expenses
11.910.1
7.57.8
9.09.3
42.440.9
20.821.1
11.811.8
Profit
9.14.1
2.11.7
−0.6−0.1
1.51.5
7.62.5
7.62.5
Per share
₹4.95₹1.69
₹4.95₹1.51
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VIVOBIOT₹13.98

Vivo Bio Tech Limited

· Pharma & Health
AnnualQuarterly₹ CroreMcap ₹21.4 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
Revenue from Operations44.946.7
Other Income0.04.8
Total Income44.951.5
Expenses
+ Employee Benefit Expense10.111.9
+ Finance Costs7.87.5
+ Depreciation & Amortisation9.39.0
Total Expenses40.942.4
EBITDA21.120.8
EBIT11.811.8
Profit
Pretax Income4.19.1
+ Current Tax1.72.1
+ Deferred Tax-0.1-0.6
Tax Expense1.51.5
Net Income2.57.6
Total Comprehensive Income2.57.6
Per Share
Basic EPS1.694.95
Diluted EPS1.514.95
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.